Biology and function of exosomes in tumor immunotherapy DOI Creative Commons
Can Liu, Cong Xia, Chenglai Xia

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 169, P. 115853 - 115853

Published: Nov. 9, 2023

Exosomes are nano-scale extracellular vesicles that found widely in various biological fluids. As messengers, exosomes deliver characteristic information from donor cells, facilitating their accumulation and subsequent transfer of to tumor immune cells. Immunotherapy is a cutting-edge strategy for cancer therapy, but it has not yet reached its full potential owing severe side effects limited efficacy. possess antigens immunostimulatory molecules can serve as cell-free vaccines induce antitumor immunity. In addition, given stability, low immunogenicity, targeting ability, represent ideal drug delivery systems immunotherapy by delivering cargoes, including non-coding ribonucleic acids (RNAs), membrane proteins, chemotherapeutic agents, cell death inducers. also be engineered precisely target However, rising star immunotherapy, impeded some challenges, the lack uniform technical standards isolation purification, need improve exosomal cargo loading efficient exosome delivery, expansion clinical trials, which currently infancy. Long-term, multi-center, large-scale trials needed evaluate performance future. Nonetheless, have demonstrated encouraging immunotherapy. this review, we summarize challenges with aim shed light on new-era tools.

Language: Английский

Neoantigens: promising targets for cancer therapy DOI Creative Commons
Na Xie, Guobo Shen, Wei Gao

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: Jan. 6, 2023

Abstract Recent advances in neoantigen research have accelerated the development and regulatory approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy antibody-based therapies, especially for solid tumors. Neoantigens are newly formed antigens generated by cells as a result various tumor-specific alterations, such genomic mutation, dysregulated RNA splicing, disordered post-translational modification, integrated viral open reading frames. recognized non-self trigger an immune response that is not subject to central peripheral tolerance. The quick identification prediction neoantigens been made possible advanced next-generation sequencing bioinformatic technologies. Compared tumor-associated antigens, highly immunogenic provide emerging targets personalized serve prospective predictors survival prognosis checkpoint blockade responses. therapies will be aided understanding mechanism underlying neoantigen-induced anti-tumor streamlining process neoantigen-based immunotherapies. This review provides overview on characterization outlines clinical applications immunotherapeutic strategies based neoantigens. We also explore their current status, inherent challenges, translation potential.

Language: Английский

Citations

468
Harnessing Nanomaterials for Cancer Sonodynamic Immunotherapy DOI
Shuang Liang, Jianjun Yao, Dan Liu

et al.

Advanced Materials, Journal Year: 2023, Volume and Issue: 35(33)

Published: March 7, 2023

Abstract Immunotherapy has made remarkable strides in cancer therapy over the past decade. However, such emerging still suffers from low response rates and immune‐related adverse events. Various strategies have been developed to overcome these serious challenges. Therein, sonodynamic (SDT), as a non‐invasive treatment, received ever‐increasing attention especially treatment of deep‐seated tumors. Significantly, SDT can effectively induce immunogenic cell death trigger systemic anti‐tumor immune response, termed immunotherapy. The rapid development nanotechnology revolutionized effects with robust induction. As result, more innovative nanosonosensitizers synergistic modalities are established superior efficacy safe profile. In this review, recent advances immunotherapy summarized particular emphasis on how be explored harness for amplifying response. Moreover, current challenges field prospects its clinical translation also presented. It is anticipated that review provide rational guidance facilitate nanomaterials‐assisted immunotherapy, helping pave way next‐generation eventually achieve durable patients.

Language: Английский

Citations

126
Plant exosome nanovesicles (PENs): green delivery platforms DOI
Min Cao,

Ningning Diao,

Xiaolu Cai

et al.

Materials Horizons, Journal Year: 2023, Volume and Issue: 10(10), P. 3879 - 3894

Published: Jan. 1, 2023

Structure of plant-derived vesicles and their bioactive applications. Created with BioRender.com

Language: Английский

Citations

68
Immunogenic PANoptosis‐Initiated Cancer Sono‐Immune Reediting Nanotherapy by Iteratively Boosting Cancer Immunity Cycle DOI
Liqiang Zhou, Jinxiao Lyu, Fang Liu

et al.

Advanced Materials, Journal Year: 2023, Volume and Issue: 36(2)

Published: Sept. 13, 2023

Abstract The cancer‐immune cycle conceptualized the mechanisms of driving T cell responses to tumors, but w as limited by immunological ignorance elicited tumor inherent immunoediting, which failed initiate and maintain adaptive immunity. Targeting specific vulnerabilities death patterns may provide unique opportunities boost antitumor effects. Here an ultrasound nanomedicine‐triggered immuno‐reediting therapeutic strategy using nano/genetically engineered extracellular vesicles, can induce highly immunogenic PANoptosis iteratively start‐up energization cancer innate immunity repeatedly liberating damage‐associated molecular patterns, thereby priming sufficient antigen‐specific cells shaping protective immune response through activating cGAS‐STING signaling pathways, is reported. Aided checkpoint blockade, reprogramming microenvironment further facilitated a prompt bridging immunity, remarkably suppressed metastatic rechallenged growth. Thus, targeting PANoptotic provides catcher against escape positive‐feedback activation gateway for overcoming resistance intractable cancers.

Language: Английский

Citations

58
Exosomes as smart drug delivery vehicles for cancer immunotherapy DOI Creative Commons
Huan Zhang, Simiao Wang,

Man Sun

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 13

Published: Jan. 17, 2023

Exosomes (Exos) as drug delivery vehicles have been widely used for cancer immunotherapy owing to their good biocompatibility, low toxicity, and immunogenicity. Some Exos-based strategies such tuning of immunosuppressive tumor microenvironment, immune checkpoint blockades, vaccines also investigated in recent years, which all showed excellent therapeutic effects malignant tumor. Furthermore, some systems (DDSs) undergone clinic trails, indicating that Exos are a promising carrier. In this review, order promote the development DDSs immunotherapy, biogenesis composition Exos, summarized. Meanwhile, clinical translation challenges discussed. We hope review will provide guidance immunotherapy.

Language: Английский

Citations

55
Cell microparticles loaded with tumor antigen and resiquimod reprogram tumor-associated macrophages and promote stem-like CD8+ T cells to boost anti-PD-1 therapy DOI Creative Commons

Xiaoqiong Zhang,

Zhaohan Wei,

Tuying Yong

et al.

Nature Communications, Journal Year: 2023, Volume and Issue: 14(1)

Published: Sept. 13, 2023

Abstract The durable response rate to immune checkpoint blockade such as anti-programmed cell death-1 (PD-1) antibody remains relatively low in hepatocellular carcinoma (HCC), mainly depending on an immunosuppressive microenvironment with limited number of CD8 + T cells, especially stem-like tumor tissues. Here we develop engineered microparticles (MPs) derived from alpha-fetoprotein (AFP)-overexpressing macrophages load resiquimod (R848@M2pep-MPs AFP ) for enhanced anti-PD-1 therapy HCC. R848@M2pep-MPs target and reprogram M2-like tumor-associated (TAMs) into M1-like phenotype. Meanwhile, -reprogrammed TAMs act antigen-presenting not only presenting antigen activate cell-mediated antitumor immunity, but also providing intra-tumoral niche maintain differentiate cells. Combination immunotherapy generates strong memory induces abundant proliferation differentiation terminally exhausted cells long-term surveillance orthotopic autochthonous HCC preclinical models male mice. We show that the R848-loaded MPs overexpressing a model ovalbumin (OVA) can improve melanoma B16-OVA tumor-bearing Our work presents facile generic strategy personalized cancer boost therapy.

Language: Английский

Citations

50
An Integrated Polymeric mRNA Vaccine without Inflammation Side Effects for Cellular Immunity Mediated Cancer Therapy DOI
Pei Huang,

Lingsheng Jiang,

Hui Pan

et al.

Advanced Materials, Journal Year: 2022, Volume and Issue: 35(3)

Published: Nov. 3, 2022

Among the few available mRNA delivery vehicles, lipid nanoparticles (LNPs) are most clinically advanced but they require cumbersome four components and suffer from inflammation-related side effects that should be minimized for safety. Yet, a certain level of proinflammatory responses innate immune activation required to evoke T-cell immunity cancer vaccination. To address these issues develop potent yet low-inflammatory vaccine vectors, series alternating copolymers "PHTA" featured with ortho-hydroxy tertiary amine (HTA) repeating units is synthesized, which can play triple roles condensing mRNA, enhancing polymeric nanoparticle (PNP) stability, prolonging circulation time. Unlike LNPs exhibiting high levels inflammation, PHTA-based PNPs show negligible inflammatory in vivo. Importantly, top candidate PHTA-C18 enables successful vivo leads robust CD8+ T cell mediated antitumor cellular immunity. Such integrated PNP provides potential approach establishing vaccines good safety profiles.

Language: Английский

Citations

56
Genetically Engineered‐Cell‐Membrane Nanovesicles for Cancer Immunotherapy DOI Creative Commons

Qinzhen Cheng,

Yong Kang, Bin Yao

et al.

Advanced Science, Journal Year: 2023, Volume and Issue: 10(26)

Published: July 6, 2023

The advent of immunotherapy has marked a new era in cancer treatment, offering significant clinical benefits. Cell membrane as drug delivery materials played crucial role enhancing therapy because their inherent biocompatibility and negligible immunogenicity. Different cell membranes are prepared into nanovesicles (CMNs), but CMNs have limitations such inefficient targeting ability, low efficacy, unpredictable side effects. Genetic engineering deepened the critical immunotherapy, enabling genetically engineered-CMN (GCMN)-based therapeutics. To date, that surface modified by various functional proteins been developed through genetic engineering. Herein, brief overview strategies for features sources is discussed, followed description GCMN preparation methods. application GCMNs directed at different immune targets addressed challenges prospects translation.

Language: Английский

Citations

31
CL4-modified exosomes deliver lncRNA DARS-AS1 siRNA to suppress triple-negative breast cancer progression and attenuate doxorubicin resistance by inhibiting autophagy DOI
Xinli Liu, Ge Zhang,

Tongyao Yu

et al.

International Journal of Biological Macromolecules, Journal Year: 2023, Volume and Issue: 250, P. 126147 - 126147

Published: Aug. 5, 2023

Language: Английский

Citations

28
G-MDSC-derived exosomes mediate the differentiation of M-MDSC into M2 macrophages promoting colitis-to-cancer transition DOI Creative Commons
Yungang Wang, Hongli Liu, Zhe Zhang

et al.

Journal for ImmunoTherapy of Cancer, Journal Year: 2023, Volume and Issue: 11(6), P. e006166 - e006166

Published: June 1, 2023

In inflammatory bowel disease microenvironment, transdifferentiation of myeloid-derived suppressor cells (MDSCs) and M2 macrophage accumulation are crucial for the transition colitis-to-cancer. New insights into cross-talk underling mechanism between MDSCs during colitis-to-cancer opening new avenues colitis-associated cancer (CAC) prevention treatment.The role underlying that granulocytic (G-MDSCs) or exosomes (Exo) regulates differentiation monocytic (M-MDSCs) macrophages were investigated using immunofluorescence, FACS, IB analysis, etc, employing siRNA antibodies. vivo efficacy mechanistic studies conducted with dextran sulfate sodium-induced CAC mice, employed IL-6 Abs STAT3 inhibitor.G-MDSCs promote M-MDSC through exosomal miR-93-5 p which downregulating activity in M-MDSC. is responsible enrichment G-MDSC (GM-Exo). Mechanistically, chronic inflammation-driven synthesis via IL-6R/JAK/STAT3 pathway. Early use enhances effect inhibitor against CAC.IL-6-driven secretion promotes involves a signaling transition. Combining inhibitors strategies inhibit IL-6-mediated production beneficial treatment CAC.

Language: Английский

Citations

27